Lamoste, Roscia .

HRN: 25-22-68  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/10/2025
CEFUROXIME 1.5GM (VIAL)
08/10/2025
08/11/2025
IVT
1.5g
Q8
LTCS
Remove - Pending Acceptance
08/11/2025
CEFUROXIME 500MG (TAB)
08/11/2025
08/17/2025
ORAL
500mg
Q12
Post CS
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: